Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH): a Multi-center Randomized, Controlled, Assessor-blinded Trial

NCT03741530 is registered in ClinicalTrials.gov with Xijing Hospital as lead sponsor.

NCT NCT03741530
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT03741530 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Glibenclamide Advantage in Treating Edema After Intracerebral Hemorrhage (GATE-ICH): a Multi-center Randomized, Controlled, Assessor-blinded Trial
Lead sponsor
Xijing Hospital
Phase
Not applicable
Overall status
Completed
Start date
December 15, 2018
Completion date
September 23, 2020
Enrollment
220 (actual)
Sites
5

Conditions

As the registry lists them; a condition with its own page is linked.

intracerebral hemorrhage